BACKGROUND: Betablockade has been shown to have cardioprotective effects in patients under perioperative stress. Besides animal model of septic shock and a small cohort of septic patients, these benefits have not been studied in septic shock patients who require norepinephrine administration. METHODS: After correction of preload, an esmolol bolus (0.2-0.5 mg/kg) followed by continuous 24 h infusion was administered in septic patients with sinus or supraventricular tachycardia (HR > 120/min). Exclusion criteria were severe LV systolic dysfunction, atrioventricular blockade and norepinephrine infusion at rates over 0.5 mg/kg/min. Monitoring with echocardiography and pulmonary artery catheter before, at 2, 6, 12, 24 h following the start and 6 h after ceasing of the esmolol drip. Patients were maintained normovolemic throughout the study and adjustments of concomitant norepinephrine infusion rates were made as required. RESULTS: Ten septic patients (mean age 54.4 ± 18.7), APACHE II 21.5 ± 6.2, CRP 275 ± 78 mg/l, procalcitonin 14.5 ± 10.1 mg/l, were given esmolol drip of 212.5 ± 63.5 mg/h at start to 272.5 ± 89.5 mg/h at 24 h. Heart rate decreased from mean 142 ± 11/min to 112 ± 9/min (p < 0.001) with parallel insignificant reduction of cardiac index (4.94 ± 0.76 to 4.35 ± 0.72 l/min/m(2)). Stroke volume insignificantly increased from 67.1 ± 16.3 ml to 72.9 ± 15.3 ml. No parallel change of pulmonary artery wedge pressure was observed (15.9 ± 3.2 to 15.0 ± 2.4 mmHg) as well as no significant changes of norepinephrine infusion (0.13 ± 0.17 to 0.17 ± 0.19 mg/kg/min), DO(2), VO(2), OER or arterial lactate. CONCLUSIONS: Saving the heart 30 beats/min did not demonstrate adverse impact on global haemodynamics in rates above 110/min. Using well titratable betablocker seems to be safe and cardioprotective in septic shock patients with high cardiac output.

Department of Anaesthesiology and Intensive Care 1st Faculty of Medicine Charles University Prague and General University Hospital Prague U Nemocnice 2 Prague 2 120 00 Prague Czech Republic

Komentář v

Wien Klin Wochenschr. 2013 Jan;125(1-2):54-5. doi: 10.1007/s00508-012-0305-z. PubMed

Zobrazit více v PubMed

Crit Care Med. 2005 Sep;33(9):1994-2002 PubMed

Crit Care Med. 2003 Apr;31(4):1250-6 PubMed

Intensive Care Med. 2008 May;34(5):917-22 PubMed

Crit Care Med. 2010 Feb;38(2):388-94 PubMed

Crit Care Med. 2005 Oct;33(10):2294-301 PubMed

Intensive Care Med. 2011 Aug;37(8):1344-51 PubMed

Am J Respir Crit Care Med. 1999 Aug;160(2):458-65 PubMed

Am J Cardiol. 2006 Jan 1;97(1):130-6 PubMed

Crit Care Med. 2008 Jun;36(6):1701-6 PubMed

Crit Care Med. 2010 Oct;38(10 Suppl):S608-12 PubMed

Shock. 2009 May;31(5):515-20 PubMed

J Mol Cell Cardiol. 2011 Oct;51(4):518-28 PubMed

Crit Care. 2010;14(4):R142 PubMed

N Engl J Med. 1999 Dec 9;341(24):1789-94 PubMed

Chest. 2004 Aug;126(2):534-9 PubMed

Crit Care Med. 2007 Jun;35(6):1599-608 PubMed

Intensive Care Med. 2010 Nov;36(11):1882-9 PubMed

Research priorities for the study of atrial fibrillation during acute and critical illness: recommendations from the Symposium on Atrial Fibrillation in Acute and Critical Care

Landiolol for heart rate control in patients with septic shock and persistent tachycardia. A multicenter randomized clinical trial (Landi-SEP)

Propafenone versus amiodarone for supraventricular arrhythmias in septic shock: a randomised controlled trial

Efficacy and safety of 1C class antiarrhythmic agent (propafenone) for supraventricular arrhythmias in septic shock compared to amiodarone: protocol of a prospective randomised double-blind study

Landiolol in patients with septic shock resident in an intensive care unit (LANDI-SEP): study protocol for a randomized controlled trial

Concomitant use of beta-1 adrenoreceptor blocker and norepinephrine in patients with septic shock. Reply to a letter to the authors